New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

13 recent FDA supplement recalls & advisories

Since their final implementation for all companies in 2010, supplement Good Manufacturing Practices (GMPs) have seen numerous violations in recent yearsa fact that's concerning for the U.S. Food and Drug Administration and for manufacturers.

A recent spate of recalls involves several disturbing instances of drug adulteration, including products using such common Rx adulterants as sibutramine, sildenafil, tadalafil and fluoxetine. FDA's checking the same old problem areas in the supplement world—weight loss, bodybuilding and sexual enhancement.

FDA has certainly stepped up enforcement in the area of adulteration, while also giving priority over the last few years to sending warning letters to companies large and small that operate in violation of GMPs, no matter how small the infraction. 

Bottom line: Despite the final implementation of GMPs, adulteration remains an unsolved problem.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.